Background: The subthalamic nucleus is the preferred target for deep brain stimulation in patients with advanced Parkinson’s disease. The site of permanent stimulation is the subject of ongoing debate ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The FDA approval covers two treatment algorithms that run on a device made by Medtronic, a medical device company. Both work ...

Both work by monitoring the same part of the brain, called the subthalamic nucleus. But they respond in different ways. A “fast” algorithm detects patterns associated with symptoms and ...